Average cost of drugs for extensively drug-resistant tuberculosis in India
India: Average cost of drugs for extensively drug-resistant tuberculosis was 1,203 constant 2022 US$ in 2024. ◆ Volatile
Latest (2024)
1,203 constant 2022 US$
Change on year
up 6.6%
World rank
39th
of 56 countries
All-time high
11,000 constant 2022 US$
in 2017
All-time low
600 constant 2022 US$
in 2021
Years of data
8
2017–2024
Average cost of drugs for extensively drug-resistant tuberculosis in India, 2017–2024
Source: WHO (2025) – with minor processing by Our World in Data. Measured in constant 2022 US$.
Analysis
The most recent figure for average cost of drugs for extensively drug-resistant tuberculosis in India is 1,203 constant 2022 US$, measured in 2024.
Compared with earlier readings it is up 6.6% on the previous year and down 89.1% over ten years.
India ranks 39th of 56 countries on this measure, in the middle of the range.
Average cost of drugs for extensively drug-resistant tuberculosis in India, year by year
| Year | constant 2022 US$ | Change |
|---|---|---|
| 2017 | 11,000 constant 2022 US$ | — |
| 2018 | 5,000 constant 2022 US$ | -54.5% |
| 2019 | 5,000 constant 2022 US$ | +0.0% |
| 2020 | 6,399 constant 2022 US$ | +28.0% |
| 2021 | 600 constant 2022 US$ | -90.6% |
| 2022 | 1,187 constant 2022 US$ | +97.8% |
| 2023 | 1,129 constant 2022 US$ | -4.9% |
| 2024 | 1,203 constant 2022 US$ | +6.6% |
India compared with similar countries
- India's 1,203 constant 2022 US$ is below the median for lower middle income countries, which is 1,525 constant 2022 US$, 79% of the median. (24 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 7,000 constant 2022 US$ | 5,000 constant 2022 US$ | 11,000 constant 2022 US$ | 3 |
| 2020s | 2,104 constant 2022 US$ | 600 constant 2022 US$ | 6,399 constant 2022 US$ | 5 |
Countries ranked near India
More reference data data for India
- Emission Totals - Indirect emissions (N2O) - Manure applied to Soils 20.88 (2050)
- Emission Totals - Indirect emissions (N2O) - Manure left on Pasture 68.88 (2050)
- Emission Totals - Indirect emissions (N2O) - IPCC Agriculture 246.78 (2050)
- Emission Totals - Indirect emissions (N2O) - Crop Residues 15.62 (2050)
- Emission Totals - Indirect emissions (N2O) - Agricultural Soils 246.78 (2050)
- Emission Totals - Emissions (N2O) - Manure applied to Soils 70.02 (2050)
- Emission Totals - Emissions (N2O) - Manure Management 19.71 (2050)
- Emission Totals - Emissions (N2O) - Manure left on Pasture 309.05 (2050)
- Emission Totals - Emissions (N2O) - IPCC Agriculture 1,063 (2050)
- Emission Totals - Emissions (N2O) - Crop Residues 85.03 (2050)
Frequently asked questions
- What is average cost of drugs for extensively drug-resistant tuberculosis in India?
- Average cost of drugs for extensively drug-resistant tuberculosis in India was 1,203 constant 2022 US$ in 2024, according to WHO (2025) – with minor processing by Our World in Data.
- What is the highest average cost of drugs for extensively drug-resistant tuberculosis recorded in India?
- The highest recorded value was 11,000 constant 2022 US$ in 2017.
- What is the lowest average cost of drugs for extensively drug-resistant tuberculosis recorded in India?
- The lowest recorded value was 600 constant 2022 US$ in 2021.
- How does India rank for average cost of drugs for extensively drug-resistant tuberculosis?
- India ranks 39th out of 56 countries with data for 2024.
- Is average cost of drugs for extensively drug-resistant tuberculosis rising or falling in India?
- Over the last ten years it is down 89.1%. The long-run trend across the full record is volatile.
- Where does this India data come from?
- The figures come from WHO (2025) – with minor processing by Our World in Data, published as part of Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 8 observations, free to reuse under CC BY 4.0 (Our World in Data).
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.